CSIMarket
 
Abeona Therapeutics Inc   (ABEO)
Other Ticker:  
 
 
Price: $6.4000 $0.02 0.313%
Day's High: $6.45 Week Perf: 5.96 %
Day's Low: $ 6.25 30 Day Perf: -2.74 %
Volume (M): 195 52 Wk High: $ 9.01
Volume (M$): $ 1,248 52 Wk Avg: $5.51
Open: $6.43 52 Wk Low: $3.05



 Market Capitalization (Millions $) 175
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -77
 Cash Flow (TTM) (Millions $) 13
 Capital Exp. (TTM) (Millions $) 1

Abeona Therapeutics Inc
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing gene and cell therapies for rare and life-threatening genetic diseases. The company is dedicated to transforming the lives of patients suffering from rare genetic diseases by developing innovative treatments that address the underlying cause of the disease.

Abeona Therapeutics has a diverse pipeline of potential therapies, with a particular focus on treating patients with rare genetic conditions such as Sanfilippo syndrome, Batten disease, and epidermolysis bullosa. The company's therapies aim to either replace missing or malfunctioning genes or to modify the patient's own cells to produce the missing proteins.

The company is committed to conducting thorough research and running clinical trials to ensure the safety and efficacy of their therapies. In addition to developing new treatments, Abeona Therapeutics also collaborates with academic institutions and other companies to improve and expand the field of gene and cell therapies.

Overall, Abeona Therapeutics Inc. is a pioneering biopharmaceutical company that strives to develop revolutionary therapies for rare genetic diseases, providing hope to patients and their families.


   Company Address: 6555 Carnegie Avenue Cleveland 44103 OH
   Company Phone Number: 813-4701   Stock Exchange / Ticker: NASDAQ ABEO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CMRX      0% 
BLUE   -12.38%    
EDIT        8.33% 
NTLA        10.5% 
NVAX   -2.3%    
SGMO        64.94% 
• View Complete Report
   



Management Announcement

Abeona Therapeutics Navigates Financial Turmoil While Inducing New Talent in Search of Breakthrough Gene Therapy Approval,

Published Fri, Nov 1 2024 11:30 AM UTC

Abeona Therapeutics Faces Financial Headwinds While Pursuing Gene Therapy Approval: A Close Look at Recent Developments and Employee InducementsAbeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company focused on developing innovative gene therapies, has recently announced the granting of equity awards to new non-executive employees as part of their...

Management Announcement

High Stakes: Abeona Therapeutics Resubmits Gene Therapy Application Amidst Financial Uncertainty,

Published Tue, Oct 29 2024 11:30 AM UTC

Abeona Therapeutics: Navigating Financial Turbulence in the Quest for Gene Therapy ApprovalCLEVELAND ? In the high-stakes world of biotech, few situations are as precarious as the race for the next groundbreaking treatment. Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company, finds itself at this critical juncture, recently resubmitting its Bi...

Shares

Abeona Therapeutics? Equity Awards: A Strategic Talent Boost or a Cautionary Sign,

Published Tue, Oct 1 2024 11:30 AM UTC

Abeona Therapeutics Induces New Talent with Equity Awards: A Strategic Move or a Sign of Challenge?Abeona Therapeutics Inc., a clinical-stage biophar...

Announcement

Leveraging Equity Awards for Workforce Enhancement Abeona Therapeutics Strategic Implementation Under Nasdaq Rule 56...

Published Thu, Aug 1 2024 11:30 AM UTC

'Equity Awards Granted to New Employees at Abeona Therapeutics Under Nasdaq Listing Rule 5635(c)(4)'' CSIMarket.com ''Abstract'Abeona Therapeutics Inc. (Nasdaq: ABEO), a pioneering company in the realm of gene and cell therapy, has announced the implementation of equity awards for newly onboarded non-executive employees. This practice aligns with provisions under Nasdaq List...

Partnership

Evaluating the Therapeutic Potential of Abeona Therapeutics AAV204 Capsid for Ophthalmology Indications

Published Thu, Jul 11 2024 11:30 AM UTC

This article provides an in-depth analysis of the partnership between Abeona Therapeutics Inc. and Beacon Therapeutics, focusing on the evaluation of Abeona's patented AAV204 capsid for the development and commercialization of potential gene therapies in select ophthalmology indications. Additionally, the financial performance of Abeona Therapeutics Inc. during the correspon...







Abeona Therapeutics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com